MFJ Stock Overview
Designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.19 |
| 52 Week High | AU$1.61 |
| 52 Week Low | AU$0.78 |
| Beta | 1.72 |
| 11 Month Change | -6.30% |
| 3 Month Change | -17.93% |
| 1 Year Change | 52.56% |
| 33 Year Change | 32.22% |
| 5 Year Change | 7.21% |
| Change since IPO | 113.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| MFJ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 0.2% |
| 1Y | 52.6% | -6.8% | 8.5% |
Return vs Industry: MFJ exceeded the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: MFJ exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| MFJ volatility | |
|---|---|
| MFJ Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: MFJ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MFJ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 254 | Swami Raote | polynovo.com |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products.
PolyNovo Limited Fundamentals Summary
| MFJ fundamental statistics | |
|---|---|
| Market cap | €853.52m |
| Earnings (TTM) | €3.28m |
| Revenue (TTM) | €64.42m |
260.0x
P/E Ratio13.2x
P/S RatioIs MFJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MFJ income statement (TTM) | |
|---|---|
| Revenue | AU$103.23m |
| Cost of Revenue | AU$16.41m |
| Gross Profit | AU$86.82m |
| Other Expenses | AU$81.56m |
| Earnings | AU$5.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0076 |
| Gross Margin | 84.11% |
| Net Profit Margin | 5.10% |
| Debt/Equity Ratio | 3.6% |
How did MFJ perform over the long term?
See historical performance and comparison